US regulators have given Elan and its partner Biogen a date for a meeting which will review the status of their suspended multiple sclerosis drug Tysabri.
A committee of the US Food & Drug Administration's meeting will take place on March 7, and will then make a recommendation to the FDA. The FDA had granted Tysabri priority review status, which means a decision is made more quickly than usual.
Elan and Biogen completed a safety review of more than 3,000 Tysabri patients following the treatment's suspension last year when a number of cases of rare brain disease PML were found in patients treated with the drug in combination with Biogen's widely used Avonex drug.
Elan shares closed 27 cent lower at €11.53 in Dublin this evening.
